Life sciences company Neogen (NASDAQ: NEOG) will be announcing earnings results this Thursday before the bell. Here’s what to expect.

Neogen beat analysts’ revenue expectations last quarter, reporting revenues of $224.7 million, down 2.8% year on year. It was a stunning quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ revenue estimates.

Is Neogen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Neogen’s revenue to decline 7.5% year on year, a further deceleration from the 3.4% decrease it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Neogen has missed Wall Street’s revenue estimates multiple times over the last two years.

With Neogen being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for healthcare equipment and supplies stocks. However, the whole sector has faced a sell-off over the last month with stocks in Neogen’s peer group down 2.5% on average. Neogen is up 4.5% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.